We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

GENinCode plc (GENI) ORD GBP0.01

Sell:5.00p Buy:5.50p 0 Change: 0.13p (2.44%)
Market closed |  Prices as at close on 17 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.00p
Buy:5.50p
Change: 0.13p (2.44%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.00p
Buy:5.50p
Change: 0.13p (2.44%)
Market closed |  Prices as at close on 17 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

Contact details

Address:
1 St. Peters Square
OXFORD
OX4 4GP
United Kingdom
Telephone:
+44 (01865) 955847
Website:
https://www.genincode.com/

Important dates

Future events
There are no future events available.
Past events
AGM 27 June 2024 27/06/24
Annual report 05 June 2024 05/06/24
Final results 03 June 2024 03/06/24
General meeting 09 January 2024 09/01/24
Interim results 20 September 2023 20/09/23

General stock information

EPIC:
GENI
ISIN:
GB00BL97B504
Market cap:
£9.29 million
Shares in issue:
176.96 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Matthew Walls
    Chief Executive Officer, Executive Director
  • Paul Foulger
    Chief Financial Officer, Executive Director, Company Secretary
  • Jordi Gilberte
    Chief Operating Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.